Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Accenture plc (ACN) vs Amgen, Inc. (AMGN) Price & Performance

Accenture plcTrade
Amgen, Inc.Trade

Price performance (Past 24H)

Key statistics

Accenture plc vs Amgen, Inc. — how do they compare? Accenture plc trades at $179.65 (market cap $110.04B), while Amgen, Inc. trades at $416.99 (market cap $224.14B). The key difference: Amgen, Inc. is far larger — about 2× Accenture plc's market cap, and Accenture plc pays the higher dividend (3.63%). Which is the better fit depends on your goals.

ACNAMGN
Market Cap
$110.04B$224.14B
Sector
TechnologyHealth
52-Week High
$288.54$417.20
52-Week Low
$124.41$271.18
Enterprise Value
$108.26B$267.45B
Dividend Yield
3.63%2.43%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Accenture plc

Accenture (ACN) trades at $178.25, up 1.44% with strong technical and fundamental momentum. The stock shows bullish technical signals with support at $174 and resistance at $181, while recent earnings consistently beat expectations with Q1 2026 EPS of $3.80 versus $3.70 expected. Revenue growth accelerated to $69.67 billion in 2025, with solid profitability margins and attractive valuation metrics including P/E of 14.36. Recent partnerships with TEPCO and AlphaSense highlight ongoing AI-driven business transformation initiatives.

Outlook remains positive with analyst consensus price target of $189.77 offering 6.5% upside potential. Key opportunities include continued AI adoption and margin expansion, while risks involve competitive pressures and potential economic slowdown affecting consulting demand. The strong buy rating consensus (66% of analysts) supports continued investor confidence in the company's growth trajectory.

Amgen, Inc.

AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.

Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Accenture plc

Accenture PLC provides management and technology consulting services and solutions. The Company delivers a range of specialized capabilities and solutions to clients across all industries on a worldwide basis. Accenture operates a network of businesses provides consulting, technology, outsourcing, and alliances.

Read more on ACN

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN